| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10211919 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 16 Pages |
Abstract
Although patients with MYC-R lymphoma have been reported to be at high risk of primary treatment failure, this was not predicted by iPET+ results. Thus, the iPET result should not be used to guide changes in front-line or consolidative therapy for these patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Hua-Jay J. Cherng, Rachel Lynn Sargent, Sunita Dwivedy Nasta, Jakub Svoboda, Stephen J. Schuster, Anthony R. Mato, April Schrank-Hacker, Jennifer J.D. Morrissette, Daniel J. Landsburg,